The Evaluation of Artificial Intelligence in Lifestyle Management of Diabetic Patients in Community
- Conditions
- Diabetes
- Interventions
- Behavioral: personalized lifestyle intervention by AI
- Registration Number
- NCT06118671
- Lead Sponsor
- Chongqing Medical University
- Brief Summary
The goal of this clinical trial is to learn about the application and effectiveness evaluation of artificial intelligence (AI) in lifestyle management of diabetic patients in community.
- Detailed Description
To determine the effectiveness of lifestyle intervention through AI on diabetic patients, whether it can improve blood sugar/ blood pressure/ body weight/ blood lipid control in people with type 1 or type 2 diabetes? Then find related risk factors. Participants will complete the basic information, diet structure, use of dietary supplements, living habits, and exercise according to the AI scale (AI scale can be entered through we-chat mini program search), and provided personalized lifestyle intervention plan according to the survey result, while the control group received routine lifestyle guidance. All included patients would fill in the patient's medication information according to the information content of the machine reading card, and follow up whether the medication is adjusted. The patient was included in the diabetes management we-chat group, followed up for 3 months /6 months according to the visit plan. The experimental group filled in the lifestyle assessment scale again, and personalized lifestyle intervention programs were provided according to the survey results, while the control group received routine follow-up and lifestyle guidance. Researchers will compare the two groups to see if the control of blood glucose, blood pressure, blood lipids and BMI of the experimental group after 6 months of AI-based lifestyle intervention was better than the control group.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 460
- Well informed of the procedures of this trial and informed consent is obtained
- 18-80 years old, gender is not limited
- Diagnosed diabetes (according to WHO1999 diagnostic criteria)
- Well compliance
- Pregnant or lactating
- Poor blood glucose control (HbA1c>11%)
- A history of malignant tumor
- Abnormal liver or renal function [defined as alanine aminotransferase (ALT)>2.5 times higher than normal range, or eGFR<30 mL/min per 1.73 m2]
- Poor blood pressure control [systolic blood pressure (SBP)>180mmHg, or diastolic blood pressure (DBP)>110mmHg
- With severe heart disease, cardiac function worse than grade II, anemia (Hb<9.0g/d1)
- Blood routine test indicates that the white blood cell count (WBC) <3*109/L
- Body Mass Index (BMI)<18.5 or ≥35kg/m2
- Drug or alcohol abuse
- Accompanying mental disorder who can't collaborate
- Abnormal digestion and absorption function
- Other endocrine diseases
- Other chronic diseases needed long-term glucocorticoid treatment
- With severe infection, immune dysfunction
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Intervention group personalized lifestyle intervention by AI giving personalized lifestyle intervention suggestions through AI
- Primary Outcome Measures
Name Time Method Change of HbA1c one year Change of HbA1c from baseline to endpoint (1 year follow-up)
- Secondary Outcome Measures
Name Time Method Change of systolic blood pressure one year Change of systolic blood pressure from baseline to endpoint
Change of diastolic blood pressure one year Reduction of diastolic blood pressure from baseline to endpoint
Change of LDL-c one year Change of LDL-c from baseline to endpoint
Trial Locations
- Locations (1)
Jinbo Hu
🇨🇳Chongqing, Chongqing, China